Volume 31 1973

Psycho—pharmacologia

Managing Editors

J. O. Cole M. Hamilton E. Jacobsen C. Kornetsky R. W. Russell

Editorial Board

D. Bovet, Sassari J. O. Cole, Boston J. Delay, Paris J. Elkes, Baltimore
M. Hamilton, Leeds H. Isbell, Lexington E. Jacobsen, København
M. E. Jarvik, Los Angeles S. S. Kety, Boston C. Kornetsky, Boston
R. W. Russell, Bedford Park M. Shepherd, London Hannah Steinberg, London
E. Strömgren, Risskov A. Wikler, Lexington

Advisory Board

M. Adler, Philadelphia N.-E. Anden, Göteborg J. Angst, Zürich J. B. Appel, Columbia, SC
S. Barondes, La Jolla A. M. Barrett, Leeds H. Barry III, Pittsburgh H. Blaschko, Oxford
D. Booth, Birmingham H. Brill, New York A. Carlsson, Göteborg
P. Carlton, New Brunswick C. K. Connors, Boston P. B. Dews, Boston
A. DiMascio, Boston E. Domino, Ann Arbor J. C. Eccles, Buffalo
U. S. von Euler, Stockholm A. Fessard, Paris M. Fink, New York
S. Fisher, Boston R. Fog, Roskilde S. Garattini, Milano S. Gershon, New York
S. C. Goldberg, Chevy Chase S. Grossman, Chicago L.-M. Gunne, Uppsala
H. Hanson, West Point J. Harvey, Iowa City H. E. Hill, Lexington
R. Hinde, Cambridge H. Hippius, München L. E. Hollister, Palo Alto
O. Hornykiewicz, Toronto E. Hosoya, Tokyo R. P. Hullin, Leeds S. Irwin, Portland
J. Jaffe, Washington W. Janke, Düsseldorf R. Jewett, Atlanta
R. T. Jones, San Francisco M. Jouvet, Lyon C. R. B. Joyce, Basel D. Joyce, London
M. Katz, Chevy Chase R. Kelleher, Boston K. F. Killam, Davis
G. Klerman, Boston N. S. Kline, Orangeburg M. H. Lader, London I. P. Lapin, Leningrad
L. Lasagna, Rochester V. Laties, Rochester A. Latz, Tel-Aviv
O. Lingjærde, Tromsø R. Lipman, Rockville A. Lubin, San Diego E. Marley, London
W. R. Martin, Lexington J. L. McGaugh, Irvine D. E. McMillan, Chapel Hill
N. Mello, Washington A. Mirsky, Boston C. Niemegeers, Beerse
S. Norton, Kansas City D. Overton, Philadelphia G. Pampiglione, London P. Pichot, Paris
R. W. Pickens, Minneapolis A. Randrup, Roskilde D. Richter, Epsom K. Rickels, Philadelphia
R. Rodnight, London J. M. Rose, Leeds R. T. Rubin, Los Angeles J. Scheel-Krüger, Roskilde
J. Schildkraut, Boston C. Schuster, Chicago C. Shagass, Philadelphia
P. Silverman, Macclesfield, Ches. F. Sjöqvist, Stockholm J. R. Smythies, Edinburgh
F. Sulser, Nashville R. Taber, Bloomfield T. Thompson, Minneapolis S. Udenfriend, Bethesda
H. Weil-Malherbe, Washington A. Weissman, Groton, CT T. Yanagita, Kawasaki
E. Zaimis, London O. Zangwill, Cambridge

Springer-Verlag
Berlin Heidelberg New York

The exclusive copyright for all languages and countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publishers.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Springer-Verlag Berlin Heidelberg New York

Printed in Germany by Wiesbadener Graphische Betriebe GmbH, Wiesbaden

© by Springer-Verlag Berlin Heidelberg 1973

Contents

Subject Index VI

Ahn, H. S., see Wyatt, R. J., *et al.* 265
Angrist, B., Sathananthan, G., Gershon, S.: Behavioral Effects of L-Dopa in Schizophrenic Patients 1
Augulis, V., see Nakamura, K., *et al.* 177

Barry, H., III, see Sofia, R. D., *et al.* 121
Bläsig, J., Reinhold, K., Herz, A.: Effect of 6-Hydroxydopamine, 5,6-Dihydroxytryptamine and Raphe Lesions on the Antinociceptive Actions of Morphine in Rats 111
Boissier, J. R., see Thiébot, M. H., *et al.* 77
Borbély, A. A., Huston, J. P., Waser, P. G.: Physiological and Behavioral Effects of Parachlorophenylalanine in the Rat 131
Boulton, C. S., Handley, S. L.: Factors Modifying the Head-Twitch Response to 5-Hydroxytryptophan 205
Brantmark, B., Ohlin, P., Westling, H.: Nicotine-Containing Chewing Gum as an Anti-Smoking Aid 191
Breese, G. R., see Cooper, B. R., *et al.* 95
Bruggen, J. A. A. Van, see Desmedt, L. K. C., *et al.* 49

Campbell, B. A., Mabry, P. D.: The Role of Catecholamines in Behavioral Arousal during Ontogenesis 253
Carlini, E. A., see Mello, A. C. de, *et al.* 349
Chute, D. L., see Wright, D. C. 91
Conney, A. H., see Nakamura, K., *et al.* 177
Cook, L., see Sepinwall, J., *et al.* 375
Cooper, B. R., Grant, L. D., Breese, G. R.: Comparison of the Behavioral Depressant Effects of Biogenic Amine Depleting and Neuroleptic Agents Following Various 6-Hydroxydopamine Treatments 95
Coyle, J. T., Jr., Wender, P., Lipsky, A.: Avoidance Conditioning in Different Strains of Rats: Neurochemical Correlates 25

Desmedt, L. K. C., Van Bruggen, J. A. A., Niemegeers, C. J. E.: The Effects of Pimozide on Dominant-Subordinate Behaviour in Wistar Rats Competing for Food 49
Domino, E. F., see Pearl, J. H., *et al.* 13
Dressler, K., see Mello, A. C. de, *et al.* 349

Fernö, O., Lichtneckert, S. J. A., Lundgren, C. E. G.: A Substitute for Tobacco Smoking 201
Fried, P. A., McIntyre, D. C.: Electrical and Behavioral Attenuation of the Anti-Convulsant Properties of Δ^9-THC Following Chronic Administration 215

Gershon, S., see Angrist, B., *et al.* 1
Glow, P. H., Russell, A.: Effects of Dexamphetamine, Amylobarbitone Sodium and Their Mixture on Sensory Contingent Bar Pressing Behaviour in the Rat 239
Goudie, A. J., see Taylor, M., *et al.* 63
Grant, L. D., see Cooper, B. R., *et al.* 95
Green, J. P., see Mello, A. C. de, *et al.* 349
Grodsky, F. S., see Sepinwall, J., *et al.* 375

Handley, S. L., see Boulton, C. S. 205
Henriksson, B. G., see Järbe, T. U. C. 321
Herz, A., see Bläsig, J., *et al.* 111
Holtzman, S. G., see Steinert, H. R., *et al.* 35
Huston, J. P., see Borbély, A. A., *et al.* 131
Hutchins, D. A., Rogers, K. J.: Some Observations on the Ciradian Rhythm of Locomotor Activity of Mice after Depletion of Cerebral Monoamines. . 343

Izquierdo, I., Nasello, A. G.: Effects of Cannabidiol and of Diphenylhydantoin on the Hippocampus and on Learning 167

Järbe, T. U. C., Henriksson, B. G.: Effects of Δ^8-THC, and Δ^9-THC on the Acquisition of a Discriminative Positional Habit in Rats 321
Jewett, R. E., see Steinert, H. R., *et al.* 35

Kang, S., see Mello, A. C. de, *et al.* 349
Kilbey, M. M., Moore, J. W., Jr.: Δ^9-Tetrahydrocannabinol Induced Inhibition of Predatory Aggression in the Rat 157
Kitsikis, A., Roberge, A. G.: Behavioral and Biochemical Effects of α-Methyltyrosine in Cats 143
Kubena, R. K., see Sofia, R. D., *et al.* 121
Kuntzman, R., see Nakamura, K., *et al.* 177

Lichtneckert, S. J. A., see Fernö, O., *et al.* 201
Lipsky, A., see Coyle, J. T., Jr., *et al.* 25
Longo, V. G., see Willinsky, M. D., *et al.* 365
Lundgren, C. E. G., see Fernö, O., *et al.* 201

Mabry, P. D., see Campbell, B. A. 253
Maggio, A. C., see Nakamura, K., *et al.* 177
Mandel, L. R., see Wyatt, R. J., *et al.* 265
Margolis, S., see Mello, A. C. de, *et al.* 349
McIntyre, D. C., see Fried, P. A. 215
Mello, A. C. de, Carlini, E. A., Dressler, K., Green, J. P., Kang, S., Margolis, S.: Behavioral Observations on Compounds Found in Nutmeg . . . 349
Moore, J. W., Jr., see Kilbey, M. M. 157
Müntzing, J., see Rohte, O. 333

Nakamura, K., Kuntzman, R., Maggio, A. C., Augulis, V., Conney, A. H.: Influence of 6-Hydroxydopamine on the Effect of Morphine on the Tail-Flick Latency 177
Nasello, A. G., see Izquierdo, I. 167
Niemegeers, C. J. E., see Desmedt, L. K. C., *et al.* 49

Ohlin, P., see Brantmark, B., *et al.* 191

Pearl, J. H., Domino, E. F., Rennick, P.: Short-Term Effects of Marijuana Smoking on Cognitive Behavior in Experienced Male Users. 13

Reinhold, K., see Bläsig, J., *et al.* 111
Rennick, P., see Pearl, J. H., *et al.* 13
Roberge, A. G., see Kitsikis, A. 143
Rogers, K. J., see Hutchins, D. A. 343
Rohte, O., Müntzing, J.: Effects of Reserpine, 6-Hydroxydopamine, p-Chlorophenylalanine and a Combination of These Substances on the Grooming Behaviour of Mice 333
Russell, A., see Glow, P. H. 239

Sathananthan, G., see Angrist, B., *et al.* 1
Scotti de Carolis, A., see Willinsky, M. D., *et al.* 365
Schuster, C. R., see Wilson, M. C. 291
Sepinwall, J., Grodsky, F. S., Sullivan, J. W., Cook, L.: Effects of Propranolol and Chlordiazepoxide on Conflict Behavior in Rats 375
Simon, P., see Thiébot, M. H., *et al.* 77

Sofia, R. D., Kubena, R. K., Barry, H., III: Inactivity of Δ^9-Tetrahydrocannabinol in Antidepressant Screening Tests 121
Soubrié, P., see Thiébot, M. H., *et al.* 77
Steinert, H. R., Holtzman, S. G., Jewett, R. E.: Some Agonistic Actions of the Morphine Antagonist Levallorphan on Behavior and Brain Monoamines in the Rat 35
Sullivan, J. W., see Sepinwall, J., *et al.* 375
Svensson, T. H., Waldeck, B.: Significance of Acetaldehyde in Ethanol-Induced Effects on Catecholamine Metabolism and Motor Activity in the Mouse 229

Taylor, M., Goudie, A. J., Williams, A.: The Effects of Chronic Fenfluramine Administration on Behaviour and Body Weight 63
Thiébot, M. H., Soubrié, P., Simon, P., Boissier, J. R.: Dissociation de deux composantes du comportement chez le rat sous l'effet de psychotropes. Application à l'étude des anxiolytiques 77

Valzelli, L.: The "Isolation Syndrome" in Mice 305
Vanden Heuvel, W. J. A., see Wyatt, R. J., *et al.* 265
Van der Poel, A. M.: Registration of Choice Direction in a T-Maze in Rats under the Influence of N-Methyl-4-Piperidyl Cyclopentyl Methylethynyl Glycolate (PCMG), a Centrally Acting Cholinolytic 271

Waldeck, B., see Svensson, T. H. 229
Walker, R. W., see Wyatt, R. J., *et al.* 265
Waser, P. G., see Borbély, A. A., *et al.* 131
Wender, P., see Coyle, J. T., Jr., *et al.* 25
Westling, H., see Brantmark, B., *et al.* 191
Williams, A., see Taylor, M., *et al.* 63
Willinsky, M. D., Scotti de Carolis, A., Longo, V. G.: EEG and Behavioral Effects of Natural, Synthetic and Biosynthetic Cannabinoids 365
Wilson, M. C., Schuster, C. R.: The Effects of Stimulants and Depressants on Cocaine Self-Administration Behavior in the Rhesus Monkey 291
Wright, D. C., Chute, D. L.: State Dependent Learning Produced by Post Trial Intrathoracic Administration of Sodium Pentobarbital 91
Wyatt, R. J., Mandel, L. R., Ahn, H. S., Walker, R. W., Vanden Heuvel, W. J. A.: Gas Chromatographic-Mass Spectrometric Isotope Dilution Determination of N,N-Dimethyltryptamine Concentrations in Normals and Psychiatric Patients 265

Indexed in Current Contents

Subject Index

A

Acetaldehyde 229
Activity analysis 63
Aggressiveness 49, 157, 305
Alternation 271
Ambivalent behaviour 271
d-Amphetamine 25
Amylobarbitone sodium 239
Analgesia 177
Anorexia 63
Antianxiety 375
Anticonvulsant 215
Antidepressant 121
Antinociceptive morphine effect 111
Anti-smoking 191
Anxiolytics 77
Avoidance 25

B

Behaviour 333, 365
Behavioural conflict 271
—, effects 1, 305
β-Blockers 375
Brain catecholamines 25, 177
—, dopamine 95
—, norepinephrine 95

C

Cannabidiol 167
Cannabinoids 365
Catecholamines 229
Cats 143
Cerebral monoamines 343
Chlordiazepoxide 375
p-Chlorophenylalanine 333, 343
Cholinolitic 271
Circadian rhythm 131, 205, 343
Cocaine 291
Cognitive behaviour 13
Conflict 375
CNS stimulation 63

D

d-Amphetamine 25
Delayed response 143
Dexamphetamine 239
5,6-Dihydroxytryptamine 111
Dimethyltryptamine 265
Diphenylhydantoin 167
Dissociated learning 321
Dominant behaviour 49
L-Dopa 1, 253
Dopamine 143
Drinking 131
Drug dissociation 91
—, mixtures 239

E

EEG 215, 365
Elemicin 349
Ethanol 229
Evoked potentials 131
Exploratory behaviour 77

F

Facilitation 167
Feeding 131
Fenfleuramine 63
Food competition 49

H

Hallucinogens 265
Hippocampus 167
Human subjects 1, 13, 191, 265
6-Hydroxydopamine 95, 111, 177, 333
5-Hydroxytryptophan 205

I

Intrinsic motivation 239
Isolation 305

L

L-Dopa 1, 253
Learning 25, 167
Levallorphan 35
Locomotion 77
Locomotor activity 35, 253, 343

M

Marijuana 13, 121, 157, 215, 321, 349
Memory 271
—, consolidation 91
Mescaline 349
α-Methyl-para-tyrosine 253, 343
4-Methylpyrazole 229
α-Methyltyrosine 95, 143
Mice 121, 205, 229, 305, 333, 343, 349
Midbrain Raphe lesion 111
Monkeys, Rhesus 291
Monoamines, cerebral 343
Morphine 177, 291
Motor activity 131, 229
Myristicin 349

N

Naloxone 35
Narcotic antagonist 35
Neuroanatomy 305

Neurochemistry 305
Nialamide 229
Nicotine 191, 201
Noradrenaline 143
Nutmeg 349

O

Oestrus cycle 205
Ontogenesis 253
Operant behaviour 35, 95

P

Parachlorphenylalanine 131
p-Chlorophenylalanine 333, 343
PCMG 271
Pentobarbital 291
Pimozide 49
Posttetanic potentiation 167
Potassium release 167
Predatory aggression 157
Propranolol 357
Psychoneurosis 305
Psychotropic drugs 77, 305
Punishment 375

Q

Quantum chemistry 349

R

Rabbits 365
Rats 25, 35, 49, 63, 77, 91, 95, 111, 121, 131, 157, 167, 177, 215, 239, 253, 271, 321, 349, 375
Rearing 77
Registration 271
Reserpine 95, 253, 333, 343
Retrograde amnesia 91
Reversal 321
Reward value enhanced 239
RNA, hippocampal 167

S

Schizophrenia 1, 265
Self-administration 291
Sensory modulation 205
—, reinforcement 239
Serotonin 143, 157
Sleep 131
Smoking, marijuana 13
—, tobacco 191, 201
Sodium pentobarbital 91
State-dependent learning 91, 321
Sterotyped behaviour 63
Subordinate behaviour 49

T

Δ^8 Tetrahydrocannabinol 321
Δ^9 —, 13, 121, 157, 215, 321, 349
T-maze 271
Tobacco withdrawal 191, 201
Tolerance 215, 349
Trifluoperazine 291

U

U-14,624 95

V

Visual discrimination 143

Instructions to Authors

1. Papers will be published in **English, French or German.**

2. Authors should submit **manuscripts together with two copies.** The original illustration material (original drawings etc.) and two copies should be submitted together with the manuscript.

3. The text should be as **clear and concise** as possible. Both form and content of the paper should be carefully checked to exclude the need for corrections in proof. A charge will be made for changes introduced after the manuscript has been set in type.

4. **Manuscripts** should be typewritten, double-spaced, on one side of letter size paper and with wider margin on the left. The author should mark in the margin where figures and tables may be inserted. All pages should be numbered consecutively. Tables, footnotes and legends for illustrations should be typed (double-spaced) on separate pages. Use the metric system for text and figures.

5. The **first page** should bear:
the title; the name(s) of the author(s); the name of the laboratory where the work was carried out; a running title of not more than 67 typewriter strokes; footnotes to the title (marked by asterisks).

6. Each paper should be preceded by a brief **abstract** in English concerned with the methods used and with the experimental results which should be presented in such a way that it is possible for the reader to assess their significance. It should be as short as possible and should **not exceed 200 words.**
French and German articles should also have an **English translation of the title.**

7. Immediately following the abstract, some relevant **key words** should be supplied for subject indexing.

8. Articles dealing with **original investigations** should first state the problem concisely and arrange the material under Methods, Results, Discussion, References.

9. **Footnotes** should be kept to a minimum and numbered consecutively throughout the paper. Footnotes referring to the heading of the article are to be marked by asterisks.

10. The **bibliography** should include only work cited in the text. References should be listed alphabetically at the end of the paper as follows: *journal papers*—names and initials of all authors, full title, journal abbreviated in accordance with World Medical Periodicals, volume number, first and last page numbers, year in parentheses; *books*—names of authors, full title, edition, place, publisher, year. *Examples:*

Latz, A., Bain, G. T., Kornetsky, C.: Attenuated effect of chlorpromazine on conditioned avoidance as a function of rapid acquisition. Psychopharmacologia (Berl.) **14**, 23—32 (1960).

Fisher, S., Cole, J. O., Rickels, K., Uhlenhuth, E. H.: Drug set interaction: The effect of expectation on drug response in outpatients. In: Neuropsychopharmacology. Bradley, P. B., Flugle, F., and Hoch, P., eds., vol. 3, pp. 149—156. Amsterdam: Elsevier 1964.

Several publications by the same author or group of authors should be listed in chronological order; those that appear in the same year should be distinguished by the suffixes a, b, c etc. Citations in the text should be given in parentheses, e.g. (Beckman, 1958; Brown, 1963), except when the author's name is part of a sentence, e.g. "Man (1966) reported that . . ." When a paper with more than two authors is cited, all authors are named the first time, but subsequently only the first author, e.g. (Miller *et al.*, 1963).

11. Figures should be separated from the text and numbered. They should be restricted to a minimum. Descriptions in captions should not be expanded in the text, nor should the same data be given in both graph and table form. Coloured or previously published illustrations are not usually accepted. Original drawings and graphs should be drawn in Indian ink with lines of uniform thickness. Where possible, **figures should be grouped,** bearing in mind maximum display area is 108×177 mm ($4^1/_4 \times 7''$). In general it should be assumed that the same degree of reduction will apply to all figures in the same paper. Inscriptions should allow for any reduction in scale—a capital letter should be about 1.8 mm high in the final version. If figures have to be redrawn for the blockmaker, this may cause considerable delay in publication. Photographs should be sharp, well-contrasted glossy prints at right angles. Authors should mark them with Letraset (Instant Lettering).

CURRENT CONTENTS® CLINICAL PRACTICE

A NEW SERVICE THAT MAKES CONTINUING MEDICAL EDUCATION EASIER

When it comes to patient care, you know you've got to stay on top of what's new. But with busy schedules giving less time for reading, it's easy to miss key journal articles relevant to your work. *Current Contents/Clinical Practice* is an easy way to keep up with what's being published.



Each week—in an easy-to-scan, pocket-sized format, *CC®/CP* will bring you reproduced *tables of contents* from 700 of the world's most important clinical journals. By spending less than an hour with *CC/CP*—it's ideal for browsing between rounds and work-ups—you'll efficiently organize your reading. No need to handle a single journal until you're ready to read the articles you've preselected by examining titles on contents pages. And you'll be able to see what's in journals you don't normally check. The hard-to-get ones. The foreign ones.

For less than $3 a week you can make *sure* you find out what's new in patient care while it's still new. Subscribe today.

©1972 ISI

Please enter my order for *Current Contents®/Clinical Practice* and invoice me later. 337

- U.S.A., Canada, & Mexico: $135 per year
- All other locations: $165 per year

☐ 2 years—save 5% ☐ 3 years—save 10% ☐ 4 years—save 15% ☐ 5 years—save 20% ☐ 6 years—save 25%

☐ Please send information on discounts available for group subscriptions.

Name_____

Organization_____

Address_____

City_____ State_____

Zip_____ Country_____

GUARANTEE: Your money refunded in full if you are not satisfied with *Current Contents/Clinical Practice* after receiving six of the weekly issues.

ISI® Institute for Scientific Information
325 Chestnut Street, Philadelphia, Pennsylvania 19106 U.S.A. Tel.: (215) 923-3300

The journal you are reading and 5000 others are regularly covered in *CURRENT CONTENTS®*.

Responsible for advertisements: L. Siegel, D-1000 Berlin 15, Kurfürstendamm 237,
Telephone: (030) 8830131, Telex: 01-85411
Springer-Verlag, Berlin · Heidelberg · New York
Printed in Germany by Wiesbadener Graphische Betriebe GmbH, D-6200 Wiesbaden

© by Springer-Verlag, Berlin Heidelberg 1973